To date, RIOK2 has been found to be highly expressed only in non-small cell lung cancer (Liu et al., 2016; Liu et al., 2018), prostate cancer (Read et al., 2013), glioblastoma (Liu et al., 2016), acute myeloid leukemia (Messling et al., 2021), and hepatocellular carcinoma cells (Delman et al., 2019). Here, RIOK2 is linked to acute myeloid leukemia.